Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a 'Buy' rating on Apellis Pharmaceuticals and raises the price target from $54 to $70.
October 06, 2023 | 3:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup maintains a 'Buy' rating on Apellis Pharmaceuticals and raises the price target from $54 to $70, indicating positive sentiment towards the stock.
The raised price target by Citigroup indicates a positive outlook for Apellis Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100